Clinical Trials Sponsored by French Innovative Leukemia Organisation

Total 69 results

French Innovative Leukemia Organisation

Terminated

Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP)

B-cell Chronic Lymphocytic Leukemia (B-CLL)

France
French Innovative Leukemia Organisation

Terminated

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Lymphoma

France
French Innovative Leukemia Organisation

Completed

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Leukemia

France
French Innovative Leukemia Organisation

Completed

Phase III Study Treatment of CLL B and C

Leukemia, Lymphocytic, Chronic
French Innovative Leukemia Organisation

Completed

Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Leukemia, Lymphocytic, Acute

France
French Innovative Leukemia Organisation

Completed

Lomustine and Intermediate Dose Cytarabine in Older Patients With AML

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation

Completed

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia (RemodelWM3)

Waldenstrom Macroglobulinemia

France
French Innovative Leukemia Organisation

Active, not recruiting

Dexamethasone Added to Intensive Chemotherapy in Older Patients With Acute Myeloid Leukemia (AML) (DEXAML-02)

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation

Completed

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg (RUXOPeg)

Myelofibrosis

France
French Innovative Leukemia Organisation

Completed

Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL

B Cell Chronic Lymphocytic Leukemia

France
French Innovative Leukemia Organisation

Terminated

Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

B-cell Lymphoma

France
French Innovative Leukemia Organisation

Terminated

Treatment of Aggressive Localized Lymphoma

B Cell Lymphoma

France
French Innovative Leukemia Organisation

Recruiting

Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease (SérieProWM)

Waldenstrom's Disease | Prognostic Index

France
French Innovative Leukemia Organisation

Recruiting

Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission (LAMSA2020)

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation

Recruiting

STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR)

Untreated Chronic Lymphocytic Leukemia

France
French Innovative Leukemia Organisation

Recruiting

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Chronic Lymphoid Leukemia

France
French Innovative Leukemia Organisation

Completed

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Myelofibrosis

France
French Innovative Leukemia Organisation

Completed

Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

Diffuse Large B-Cell Lymphoma

France
French Innovative Leukemia Organisation

Completed

High-Dose Therapy Treatment in Patients With Follicular Lymphoma

Follicular Lymphoma

France
French Innovative Leukemia Organisation

Completed

Liposomal Anthracyclin in the Treatment of Elderly ALL

Acute Lymphoblastic Leukemia

France
French Innovative Leukemia Organisation

Completed

Treatment of Disseminated High Grade Lymphoma

Lymphoma

France
French Innovative Leukemia Organisation

Completed

Treatment of Localized Low Grade Lymphomas

Lymphoma, Low-Grade

France
French Innovative Leukemia Organisation
Amgen

Completed

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Richter Syndrome

France
French Innovative Leukemia Organisation
Acute Leukemia French Association

Not yet recruiting

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

AML, Adult

France
French Innovative Leukemia Organisation
Acute Leukemia French Association

Completed

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE (ELEGANCE)

Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
French Innovative Leukemia Organisation
Acute Leukemia French Association

Not yet recruiting

Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine (VENAZA)

AML, Adult

France
French Innovative Leukemia Organisation
Amgen

Completed

Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas (073)

Lymphoma

France
French Innovative Leukemia Organisation
Acute Leukemia French Association

Recruiting

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)

AML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
French Innovative Leukemia Organisation
Fresenius Kabi

Completed

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients (FAMYLY)

Acute Myeloid Leukemia (AML)

France
French Innovative Leukemia Organisation
Celgene Corporation

Completed

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Active, not recruiting

Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy (EPAG2015)

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Terminated

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Essential Thrombocythemia

France
French Innovative Leukemia Organisation
Janssen, LP

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

Relapsed or Refractory Chronic Lymphocytic Leukemia

France
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Completed

Phase I Study in RAD 001 Patients With Relapse AML

AML

France
French Innovative Leukemia Organisation
Roche Pharma AG

Completed

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

B-cell Chronic Lymphocytic Leukemia CLL

France
University Hospital, Angers
French Innovative Leukemia Organisation

Unknown

Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

Adult Acute Lymphoblastic Leukemia

France
French Innovative Leukemia Organisation
Hoffmann-La Roche

Completed

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Mantle Cell Lymphoma

France
French Innovative Leukemia Organisation
Hoffmann-La Roche

Recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (GLORIFY)

Richter Syndrome

France
French Innovative Leukemia Organisation
University Hospital, Lille

Recruiting

Observatory of Prolymphocytic Leukemia T (T-PLL)

Prolymphocytic Leukemia | T-cell Leukemia

France
French Innovative Leukemia Organisation
Bristol-Myers Squibb

Completed

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy (RESIST)

Small Lymphocytic Leukemia | CLL, Relapsed | CLL, Refractory | Bruton Tyrosine Kinase Inhibitor

France
University Hospital, Toulouse
French Innovative Leukemia Organisation

Completed

Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients (LAM-RAPA)

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation
Lymphoma Study Association

Completed

Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

Mantle Cell Lymphoma

France
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.

Completed

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

T-cell Lymphoma

France
University Hospital, Grenoble
French Innovative Leukemia Organisation

Completed

Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma (LTP)

Peripheral T Cell Lymphoma

France
French Innovative Leukemia Organisation
Novartis; Schering SA

Completed

GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly

Acute Myeloid Leukemia

France
The Lymphoma Academic Research Organisation
French Innovative Leukemia Organisation

Completed

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (T³)

Mantle Cell Lymphoma Refractory

France
French Innovative Leukemia Organisation
Acute Leukemia French Association; French Intergroup of Myeloproliferative...

Recruiting

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (CPX-351 TA-SMP)

Acute Myeloid Leukemia | Myeloproliferative Syndrome

France
French Innovative Leukemia Organisation
French Intergroup of Myeloproliferative syndromes

Completed

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias (COVIM)

Myeloproliferative Neoplasm | COVID-19 Infection

France
French Innovative Leukemia Organisation
Genzyme, a Sanofi Company; Acute Leukemia French Association

Terminated

Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia (PRIMAL)

Acute Myeloid Leukemia

France
French Innovative Leukemia Organisation
AbbVie; Janssen-Cilag Ltd.

Active, not recruiting

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC)

Intermediate Risk Chronic Lymphocytic Leukemia | Fit Patients | Risk-Adapted and MRD-Driven Strategy

France

Clinical Trials Sponsored by French Innovative Leukemia Organisation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations